Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)266.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.59k
  • 1 Year change+16.92%
  • Beta-0.7202
Data delayed at least 20 minutes, as of Jun 08 2023 16:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-24.72m
  • Incorporated2006
  • Employees40.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151
  • Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Sareum Holdings Plc0.00-2.76m88.49m5.00--30.67-----0.0406-0.04060.000.04240.00----0.00-59.88-64.34-64.48-71.09-------16,059.92----0.00-------44.76---28.45--
Redx Pharma PLC12.65m-29.01m93.78m71.00--6.28--7.41-0.0883-0.08830.0390.04460.3056--47.28---70.08-44.98-148.14-70.15-----229.35-164.47----0.5574--86.25-9.3116.55--11.21--
Celadon Pharmaceuticals PLC24.00k-17.01m97.13m----12.66--4,047.08-0.3116-0.31160.00040.12450.0024--0.0142---175.35---182.10---20,479.17---72,545.84--5.27-1.430.397--------------
e-Therapeutics plc475.00k-8.27m103.13m38.00--3.12--217.12-0.0154-0.01540.00090.05680.0148--1.9212,500.00-25.79-33.25-27.10-35.11100.00100.00-1,741.90-1,490.90----0.0089---0.4193---2.53--24.22--
Open Orphan PLC48.48m-776.00k103.51m235.00--5.0648.062.14-0.0012-0.00120.07230.03011.04--4.44206,285.10-1.66-15.59-3.59-31.13-----1.60-17.761.40--0.0718--31.5026.01-948.65--24.47--
Animalcare Group Plc71.62m1.97m109.07m211.0056.091.3811.171.520.03240.03241.181.310.62752.606.92--1.720.08772.050.102656.7752.292.740.15620.91217.670.12652,045.05-3.25--2,651.95------
Scancell Holdings Plc0.00-8.44m121.74m40.00--7.86-----0.0104-0.01040.000.01890.00----0.00-20.30-31.06-21.45-33.18-----------19.720.3805------86.66--83.42--
Futura Medical PLC0.00-5.85m123.90m12.00--26.25-----0.0203-0.02030.000.01640.00----0.00-63.98-75.22-80.95-106.12-------88,144.94----0.00-------17.93--67.85--
Silence Therapeutics plc17.50m-40.49m164.96m116.00--26.13--9.43-0.4025-0.40250.17590.20470.1718--28.09150,870.70-39.75-43.18-48.53-53.3537.83---231.35-422.12----0.0198--40.97305.31-2.74--149.02--
Faron Pharmaceuticals Oy0.00-24.72m168.90m40.00---------0.4467-0.44670.00-0.16510.00----0.00-234.98-189.70-844.50-554.55-------527,542.10---21.037.40-------35.46--31.48--
Bioventix PLC12.88m8.42m195.74m16.0023.4318.6722.8815.191.601.602.452.011.151.673.00805,240.0075.3553.9283.0057.7594.1592.5565.3364.968.13--0.0076.927.2210.0914.019.29-11.5319.83
Data as of Jun 08 2023. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX

Institutional shareholders

14.44%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 27 Jan 20232.64m4.16%
Fj�rde AP-fondenas of 31 Mar 20222.63m4.15%
Skandinaviska Enskilda Banken AB (Denmark)as of 31 Mar 20222.22m3.50%
Rhenman & Partners Asset Management ABas of 31 Dec 2021500.00k0.79%
Sp-Fund Management Co. Ltd.as of 28 Apr 2023358.12k0.56%
Fondita Fund Management Co. Ltd.as of 30 Apr 2023316.22k0.50%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2022189.19k0.30%
Aktia Varainhoito Oyas of 31 Oct 2021117.37k0.19%
Janus Henderson Investors UK Ltd.as of 30 Apr 2023100.00k0.16%
Danske Bank A/S (Investment Management Finland)as of 28 Apr 202390.95k0.14%
More ▼
Data from 31 Mar 2023 - 02 Jun 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.